1. Home
  2. REE vs LEXX Comparison

REE vs LEXX Comparison

Compare REE & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.55

Market Cap

17.1M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.66

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
LEXX
Founded
2011
2004
Country
Israel
Canada
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1M
18.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
REE
LEXX
Price
$0.55
$0.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.75
$1.50
AVG Volume (30 Days)
90.2K
152.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.46
52 Week High
$8.07
$1.90

Technical Indicators

Market Signals
Indicator
REE
LEXX
Relative Strength Index (RSI) 40.17 42.07
Support Level $0.54 $0.60
Resistance Level $0.60 $0.69
Average True Range (ATR) 0.04 0.07
MACD 0.00 -0.00
Stochastic Oscillator 39.24 26.96

Price Performance

Historical Comparison
REE
LEXX

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: